Predicting Outcomes in Diffuse Large B-Cell Lymphoma

Pretreatment levels of circulating tumor DNA and the rapidity of clearance with therapy were predictive of 2-year responses.

Currently available clinical prognostic scoring systems and correlative biomarkers are insufficient for predicting outcomes in diffuse large B-cell lymphoma (DLBCL). Now, investigators report the use of circulating tumor DNA (ctDNA) levels in peripheral blood at diagnosis and the kinetics of ctDNA clearance following treatment initiation to predict outcomes in patients with DLBCL.

The training set included 217 patients at 6 centers to establish ctDNA response thresholds based on log-reduction from baseline levels following the first treatment cycle (early molecular response [EMR]; 2-log reduction) and the second treatment cycle (major molecular response [MMR]; 2.5-log reduction) of initial induction or re-induction immunochemotherapy.

In a va…

Reviewing Author

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Predicting Outcomes in Diffuse Large B-Cell Lymphoma

Topics

Reviewing Author